Summary of findings 2. Outcome of follow‐up testing using a CEA threshold of 2.5 µg/L.
Month when CEA measured | per 1000 patients tested at a threshold of 2.5 µg/L | False alarm rate | ||||
Estimated recurrences¹ | Referrals for raised CEA | Cases of recurrence detected | Cases of recurrence missed | False alarms (cases investigated when cancer not present) | ||
Follow‐up years 1 and 2: 3‐monthly CEA testing | ||||||
3 | 19 | 212 | 16 | 3 | 196 | 92% |
6 | 19 | 212 | 16 | 3 | 196 | 92% |
9 | 39 | 224 | 32 | 7 | 192 | 86% |
12 | 39 | 224 | 32 | 7 | 192 | 86% |
15 | 37 | 223 | 30 | 7 | 193 | 87% |
18 | 37 | 223 | 30 | 7 | 193 | 87% |
21 | 31 | 219 | 25 | 6 | 194 | 89% |
24 | 31 | 219 | 25 | 6 | 194 | 89% |
Follow‐up years 3, 4 and 5: 6‐monthly CEA testing | ||||||
30 | 46 | 229 | 38 | 8 | 191 | 83% |
36 | 36 | 223 | 30 | 6 | 193 | 87% |
42 | 27 | 217 | 22 | 5 | 195 | 90% |
48 | 25 | 216 | 21 | 4 | 195 | 90% |
54 | 17 | 211 | 14 | 3 | 197 | 93% |
60 | 14 | 208 | 11 | 3 | 197 | 95% |
1Estimates are based on data reported by Sargent 2007. Three‐monthly data were unavailable, and so constant rates were assumed during each six‐month period for the first two years. Estimates are rounded.